Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.01 USD | -0.32% |
|
+3.09% | +4.14% |
Feb. 06 | Scotiabank Adjusts Bio-Techne's Price Target to $90 From $88 | MT |
Feb. 06 | KeyBanc Adjusts Bio-Techne's Price Target to $90 From $80 | MT |
Business description: Bio-Techne Corporation
- biological and chemical reagents and analysis tools 71.5%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (28.1%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ;
- other (0.4%).
Net sales are distributed geographically as follows: the United States (56.7%), the United Kingdom (4.3%), Europe-Middle East-Africa (20.8%), China (8.6%), Asia-Pacific (6.5%) and others (3.1%).
Number of employees: 3,100
Sales by Activity: Bio-Techne Corporation
Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Protein Sciences | 555M | 705M | 832M | 846M | 831M |
Diagnostics and Spatial Biology | 185M | 228M | 275M | 293M | 326M |
Other Revenue | - | - | - | - | 4.15M |
Intersegment Revenue | -1.21M | -1.28M | -1.56M | -1.65M | -2.39M |
Geographical breakdown of sales: Bio-Techne Corporation
Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States | 404M | 502M | 614M | 642M | 658M |
EMEA, Excluding United Kingdom | 155M | 204M | 219M | 220M | 241M |
Greater China | 68.79M | 87.56M | 112M | 114M | 99.47M |
APAC, Excluding Greater China | 60.36M | 69.01M | 76.14M | 73.19M | 73.9M |
United Kingdom | 30.41M | 40.94M | 48.64M | 49.46M | 50.01M |
Rest of World | 19.43M | 27.17M | 35.22M | 37.49M | 36.5M |
Managers: Bio-Techne Corporation
Director | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 58 | 2024-01-31 |
James Hippel
DFI | Director of Finance/CFO | 54 | 2014-03-31 |
David Clair
IRC | Investor Relations Contact | - | 2019-09-30 |
Matthew McManus
PRN | Corporate Officer/Principal | 56 | 2024-01-07 |
Shane Bohnen
LAW | General Counsel | 50 | 2023-03-02 |
Members of the board: Bio-Techne Corporation
Manager | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 2012-11-01 | |
John Higgins
BRD | Director/Board Member | 55 | 2009-05-18 |
Alpna Seth
BRD | Director/Board Member | 62 | 2017-10-25 |
Joseph Keegan
BRD | Director/Board Member | 72 | 2017-10-25 |
Rupert Vessey
BRD | Director/Board Member | 60 | 2019-06-25 |
Kim Kelderman
BRD | Director/Board Member | 58 | 2023-10-31 |
Julie Bushman
BRD | Director/Board Member | 64 | 2020-07-30 |
Judith Klimovsky
BRD | Director/Board Member | 68 | 2024-04-23 |
Amy E. Herr
BRD | Director/Board Member | - | 2024-12-31 |
Company details: Bio-Techne Corporation

Other Biotechnology & Medical Research
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.32% | +3.09% | +11.34% | -26.83% | 11.96B | ||
0.00% | +3.76% | +37.04% | -1.67% | 49.15B | ||
+2.20% | +4.05% | -2.53% | -15.98% | 37.29B | ||
+1.51% | +0.44% | +3.85% | +24.70% | 26.22B | ||
-0.24% | -2.87% | -26.19% | -26.62% | 16.22B | ||
-0.12% | +0.41% | +64.57% | +75.48% | 15.81B | ||
-3.92% | -18.10% | -66.40% | -79.38% | 13.46B | ||
+1.64% | +3.12% | +19.29% | +110.17% | 11.01B | ||
-6.06% | +13.64% | - | - | 10.89B | ||
-3.11% | -4.65% | -7.90% | -19.58% | 9.46B | ||
Average | +0.06% | +1.03% | +3.68% | +4.48% | 20.15B | |
Weighted average by Cap. | +0.40% | +1.91% | +9.46% | +1.94% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TECH Stock
- Company Bio-Techne Corporation